


### ABSTRACT OF THE DISCLOSURE

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:



5

A is O, S, or NR<sup>4</sup>; B is a bond or CR<sup>5</sup>R<sup>6</sup>;

R<sup>4</sup>, to R<sup>6</sup> are H, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>2</sub> to C<sub>6</sub> alkenyl, C<sub>2</sub> to C<sub>6</sub> alkynyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, aryl, or heterocyclic, or R<sup>4</sup> and R<sup>5</sup> are fused to form a ring; R<sup>1</sup> is H, OH, NH<sub>2</sub>, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>3</sub> to C<sub>6</sub> alkenyl, alkynyl, or COR<sup>A</sup>, R<sup>A</sup> is as defined; R<sup>2</sup> is H, halogen, CN, NO<sub>2</sub>, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> alkoxy, or C<sub>1</sub> to C<sub>6</sub> aminoalkyl; R<sup>3</sup> is a substituted benzene ring, or heteroaromatic ring, in combination with a progestational agent and/or an estrogen to treat or prevent secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adenocarcinomas, and contraception, among others.

10  
15